Klinische Forschung Osnabrueck

The medical center is at the forefront of research in atopic dermatitis, focusing on innovative treatments and long-term management strategies. The center's studies explore the safety and efficacy of novel therapies, such as amlitelimab and lebrikizumab, for patients with moderate to severe conditions.

• Long-term safety of amlitelimab
• Lebrikizumab efficacy in adolescents and adults
• Moisturizer impact on eczema relapse in children

These studies contribute significantly to understanding the chronic nature of atopic dermatitis and developing effective management plans for diverse patient demographics.

Specializing in allergic rhinitis and rhinoconjunctivitis, the center conducts comprehensive research on immunotherapy solutions. The focus is on the efficacy of PURETHAL Mites Mixture in treating conditions induced by house dust mite allergies.

• Subcutaneous immunotherapy for HDM-induced conditions
• Clinical efficacy of PM Mixture

This research aims to enhance therapeutic options for patients suffering from severe allergic reactions, improving their quality of life through targeted treatment approaches.

The center is pioneering research in chronic spontaneous urticaria, focusing on the development of effective treatments like povorcitinib. This research evaluates the drug's efficacy in managing symptoms and improving patient outcomes.

• Efficacy of povorcitinib in CSU

By advancing treatment options, the center aims to provide relief for patients with chronic urticaria, addressing both the physical and psychological impacts of the condition.